Favorable Outcome in a Pregnancy With Complete Fetal Heart Block and Severe Bradycardia

V. Minassian,A. Jazayeri

DOI: https://doi.org/10.1016/S0029-7844(02)02071-9

2002-11-01

Obstetrics and Gynecology

Abstract:

What problem does this paper attempt to address?

Genetic Analysis of Biopsy Tissues from Colorectal Tumors in Patients with Ulcerative Colitis

Noriko Yamamoto,Yuji Urabe,Hikaru Nakahara,Takeo Nakamura,Daisuke Shimizu,Hirona Konishi,Kazuki Ishibashi,Misa Ariyoshi,Ryo Miyamoto,Junichi Mizuno,Takeshi Takasago,Akira Ishikawa,Akiyoshi Tsuboi,Hidenori Tanaka,Ken Yamashita,Yuichi Hiyama,Yoshihiro Kishida,Hidehiko Takigawa,Toshio Kuwai,Koji Arihiro,Fumio Shimamoto,Shiro Oka

DOI: https://doi.org/10.3390/cancers16193271

2024-09-27

Cancers

Abstract:Background/Objectives: Colorectal neoplasia developing from ulcerative colitis mucosa (CRNUC) can be divided into ulcerative colitis-associated neoplasia (UCAN) and non-UCAN; however, it is often difficult to distinguish UCAN from non-UCAN during a biopsy diagnosis. We investigated whether a genomic analysis could improve the diagnostic accuracy of UCAN using biopsy specimens. Methods: In step 1, 14 CRNUCs were used to examine whether the genomic landscape of biopsy and resection specimens matched. In step 2, we investigated the relationship between the genomic landscapes and the pathological diagnosis of 26 CRNUCs. The cancer genome was analyzed by deep sequencing using a custom panel of 27 genes found to be mutated in our previous CRNUC analysis. Results: In step 1, of the 27 candidate genes, 14 were mutated. The concordance rate of the pathogenic mutations in these 14 genes between the biopsy and resection specimens was 29% (4/14), while that of the pathogenic mutations in TP53 and KRAS was 79% (11/14). In step 2, the pathological diagnosis of biopsy specimens using only hematoxylin and eosin (HE) staining had a sensitivity of 33% and an accuracy of 38% for UCAN diagnosis. On the other hand, the combination of the HE pathology and p53 immunohistochemical staining had a sensitivity of 73% and an accuracy of 85% for UCAN diagnosis, while the combination of HE staining and a TP53 mutation had a sensitivity of 87% and an accuracy of 88% for UCAN diagnosis. Conclusions: An evaluation of TP53 mutations in biopsy specimens may be useful for diagnosing UCAN. However, further studies with larger sample sizes are required before this can be applied in clinical practice.

oncology
P412 Time trend in clinicopathological features and prognosis of Ulcerative Colitis associated neoplasia: A nationwide cohort in Japan

K Komatsu,T Shinagawa,T Noguchi,M Uchino,H Ikeuchi,K Okabayashi,S Tanaka,K Futami,M Itabashi,K Watanabe,H Nagahara,Y Okita,Y Shimada,Y Mizuuchi,K Okamoto,K Yamada,Y Sato,T Mizushima,H Kimura,K Takahashi,K Hida,Y Kinugasa,F Ishida,J Okuda,K Daito,T Yamamoto,S Yamamoto,F Koyama,T Hanai,K Komori,D Shida,J Arakaki,Y Akagi,S Yamaguchi,H Ueno,K Matsuda,Y Ajioka,K Sugihara,S Ishihara,

DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0542

2023-01-30

Journal of Crohn's and Colitis

Abstract:Abstract Background With an increase in the number of Ulcerative Colitis (UC) patients in Japan, UC associated neoplasia (UCAN) cases have been accumulated. Laparoscopic surgery for sporadic advanced colorectal cancer was approved in 2002 and biologic agents have been approved for UC from 2010 in Japan. However, few reports have ever examined the time trend using a large patient cohort. We aimed to clarify time trend in clinicopathological features and prognosis of UCAN with a nationwide cohort. This study was conducted as a sub-analysis of the nationwide retrospective study across 47 institutions from the Japanese Society for Cancer of the Colon and Rectum. Methods A total of 1,139 UCAN patients were identified in the nationwide cohort from 1983 to 2020. Clinicopathological features, 5-year cancer specific survival (CSS) and overall survival (OS) were compared among the following three groups by the period of UCAN diagnosis, before 2000, 2001-2010 and 2011-2020 (the results are shown in this order). Results The number of UCAN patients registered in the database were 59, 340 and 740 in each period. Age at UCAN diagnosis (47, 51, 54, median, p<0.01) and the disease duration from UC diagnosis to UCAN diagnosis (14.3, 16.0, 17.5 years, mean, p<0.01) increased through the study periods. The rate of a surveillance colonoscopy as a diagnostic procedure (36.2%, 58.6%, 72.8%, p<0.01) increased without a change in the ratios of early (pathological stage 0-I) neoplasia (60.7%, 59.5%, 62.2%, p=0.72). Laparoscopic surgery became a dominant surgical procedure in the recent cases (1.7%, 33.2%, 47.7%, p<0.01) without an increase in postoperative complication rate (39.7%, 29.2%, 29.8%, p=0.26). Improvement in 5-year CSS (77.2%, 87.5%, 90.7%, p<0.05) and OS (77.2%, 84.3%, 88.5%, p<0.05) was observed. Among pathological stage III patients, better curative resection rate (66.7%, 92.6%, 97.1%, p<0.01) and the more use of adjuvant chemotherapy in the last decade (50.0%, 58.5%, 76.6%, p<0.05) were observed. Conclusion Longer duration of UC before the diagnosis of UCAN was observed in recent cases, which might be due to the improvement of medical therapy, including biologic agents. Minimally invasive surgery prevailed without an increase in postoperative complications. Curative resection and adjuvant chemotherapy might play a role in improvement of 5-year CSS and OS.

gastroenterology & hepatology
Molecular characterization of ulcerative colitis-associated colorectal carcinomas

Daniela Hirsch,Julia Hardt,Christian Sauer,Kerstin Heselmeyer-Hadded,Stephanie H. Witt,Peter Kienle,Thomas Ried,Timo Gaiser

DOI: https://doi.org/10.1038/s41379-020-00722-5

IF: 8.209

2020-12-14

Modern Pathology

Abstract:Patients with ulcerative colitis (UC) are at increased risk for developing colorectal cancer (CRC). In contrast to sporadic colorectal tumorigenesis, TP53 mutations occur early in the progression from inflamed colonic epithelium to dysplasia to CRC, and are sometimes readily detectable in inflamed, (yet) non-dysplastic mucosa. Here, we analyzed formalin-fixed paraffin-embedded tissue samples from 19 patients with long-standing UC (median 18 years, range 3 to 34) who had developed CRC as a consequence of chronic inflammation of the large bowel. We performed microsatellite instability testing, copy number analysis by array-based comparative genomic hybridization, mutation analysis by targeted next generation sequencing (48-gene panel) and TP53 immunostaining. The results were compared to The Cancer Genome Atlas (TCGA) data on sporadic CRC. All UC-CRC lesions in our cohort were microsatellite stable. Overall, genomic imbalances of UC-CRCs showed patterns of chromosomal aneuploidies characteristic for sporadic CRC with the exception of gains of chromosome arm 5p (12 of 23 UC-CRC, 52%), which are rare in sporadic CRCs from TCGA (21 of 144, 15%; FDR adjusted P = 0.006). UC-CRCs showed a predilection for TP53 alterations, which was the most frequently mutated gene in our cohort (20 of 23, 87%). Interestingly, spatially separated tumor lesions from individual patients tended to harbor distinct TP53 mutations. Similar to CRCs arising in a background of Crohn's colitis, the genetic landscape of UC-CRCs was characterized by TP53 mutations and chromosomal aneuploidies including gains of chromosome arm 5p. Both alterations harbor the potential for early detection in precursor lesions, thus complementing morphologic diagnosis.

pathology
Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer

Shoko Kitazawa,Tatsuyuki Chiyoda,Kohei Nakamura,Kensuke Sakai,Tomoko Yoshihama,Hiroshi Nishio,Yusuke Kobayashi,Takashi Iwata,Kouji Banno,Wataru Yamagami,Hiroshi Nishihara,Daisuke Aoki

DOI: https://doi.org/10.1007/s10147-023-02398-8

Abstract:Background: Japan's health insurance covers multigene panel testing. This study aimed to determine the potential availability and utility of gene panel testing clinically in gynecologic oncology. Methods: We analyzed the characteristics of patients with gynecologic cancer who underwent gene panel testing using FoundationOne® CDx or OncoGuide™ NCC Oncopanel between November 2019 and October 2022. Results: Out of 102 patients analyzed, 32, 18, 43, 8, and 1 had cervical, endometrial, ovarian cancers, sarcoma, and vaginal cancer, respectively. Druggable gene alteration was found in 70 patients (68.6%; 21 with cervical cancer, 15 with endometrial cancer, 28 with ovarian cancer, 5 with sarcoma, and 1 with other). The most common druggable gene alteration was PIK3CA mutation (n = 21), followed by PTEN mutation (n = 12) and high tumor mutation burden (TMB-H) (n = 11). TMB-H was detected in 5 patients with cervical cancer, 5 with endometrial cancer, and 1 with endometrial stromal sarcoma. Eleven patients (10.8%) received molecularly targeted therapy according to their gene aberrations. Gene panel testing was mostly performed when the second-line treatment was ineffective. Of all 102 patients, 60 did not have recommended treatment, and 15 died or had worsened conditions before obtaining the test results. Conclusion: Through multigene panel testing, although many patients had druggable gene alterations, 10.8% of them received the recommended treatment. TMB-H was mainly observed in cervical/endometrial cancer, suggesting its potential as a therapeutic biomarker of immune checkpoint inhibitors. Furthermore, patients' prognosis and performance status should be considered before performing the test.
Ki‐67 distribution, α‐methylacyl‐CoA racemase (AMACR) expression and mucin phenotypes are associated with non‐polypoid growth in ulcerative colitis‐associated neoplasia

Soh Okano,Masayuki Fukata,Takashi Murakami,Shuko Nojiri,Makoto Kodama,Keiko Abe,Tetsuo Yamana,Tsuyoshi Saito,Takashi Yao

DOI: https://doi.org/10.1111/his.15243

2024-06-23

Histopathology

Abstract:The basal distribution pattern of Ki‐67, normal expression of AMACR and a non‐intestinal mucin phenotype are considered as immunohistochemical features in favour of UCAN. In particular, non‐polypoid growth suggests conventional UCAN. Aims Ulcerative colitis‐associated neoplasia (UCAN) is characterised by multifocal tumourigenesis. A wide range of metachronous lesions have been reported to occur after endoscopic treatment of UCAN, which suggests the development of sporadic tumours in lesions treated as UCAN. Therefore, we aimed to evaluate differences of immunohistochemistry (IHC) in features and clinicopathological characteristics of intramucosal lesions in patients with ulcerative colitis (UC). Methods and results We examined 35 intramucosal lesions resected for carcinoma or dysplasia by total colectomy from patients with UC and 71 sporadic adenomas (SAs) endoscopically resected from patients without UC. UC lesions were divided into the conventional UCAN group, defined as p53 mutant pattern and normal expression of β‐catenin, and the non‐conventional UCAN group, defined as the rest. Ki‐67 distribution, α‐methylacyl‐CoA racemase (AMACR) expression and mucin phenotypes were compared using IHC, and clinicopathological characteristics were investigated. Conventional and non‐conventional UCAN lesions were located in the left colon and rectum. Relative to the SA lesions, UCAN lesions occurred in much younger patients and exhibited more frequent basal distribution of Ki‐67 in tumour crypts. Conventional UCAN lesions tended to be non‐polyploid and exhibited a higher frequency of normal AMACR expression than SA lesions. UC lesions were heterogeneous—only two of the eight patients with multiple lesions had lesions (both non‐conventional UCAN lesions) exhibiting concordant IHC staining features. Conclusions The basal pattern of Ki‐67 distribution, normal expression of AMACR and a non‐intestinal mucin phenotype were determined as characteristic features suggestive of UCAN. Non‐polypoid growth was another a key feature of UCAN.

pathology,cell biology
Gene Signature Distinguishes Patients with Chronic Ulcerative Colitis Harboring Remote Neoplastic Lesions

Joel Pekow,Urszula Dougherty,Yong Huang,Edward Gometz,Jeff Nathanson,Greg Cohen,Shawn Levy,Masha Kocherginsky,Nanda Venu,Maria Westerhoff,John Hart,Amy E. Noffsinger,Stephen B. Hanauer,Roger D. Hurst,Alessandro Fichera,Loren J. Joseph,Qiang Liu,Marc Bissonnette

DOI: https://doi.org/10.1097/mib.0b013e3182802bac

2013-01-01

Inflammatory Bowel Diseases

Abstract:Background: Individuals with ulcerative colitis (UC) are at increased risk for colorectal cancer. The standard method of surveillance for neoplasia in UC by colonoscopy is invasive and can miss flat lesions. We sought to identify a gene expression signature in nondysplastic mucosa without active inflammation that could serve as a marker for remote neoplastic lesions.Methods: Gene expression was analyzed by complementary DNA microarray in 5 normal controls, 4 UC patients without dysplasia, and 11 UC patients harboring remote neoplasia. Common gene ontology pathways of significantly differentially expressed genes were identified. Expression of genes which were progressively and significantly upregulated from controls to UC without neoplasia, to UC with remote neoplasia were evaluated by real-time polymerase chain reaction. Several gene products were also examined by immunohistochemistry.Results: Four hundred and sixty-eight genes were significantly upregulated, and 541 genes were significantly downregulated in UC patients with neoplasia compared with UC patients without neoplasia. Nine genes (ACSL1, BIRC3, CLC, CREM, ELTD1, FGG, S100A9, THBD, and TPD52L1) were progressively and significantly upregulated from controls to nondysplastic UC to UC with neoplasia. Immunostaining of proteins revealed increased expression of S100A9 and REG1 alpha in UC-associated cancer and in nondysplastic tissue from UC patients harboring remote neoplasia compared with UC patients without neoplasia and controls.Conclusions: Gene expression changes occurring as a field effect in the distal colon of patients with chronic UC identify patients harboring remote neoplastic lesions. These markers may lead to a more accurate and less invasive method of detection of neoplasia in patients with inflammatory bowel disease. (Inflamm Bowel Dis 2013;19:461-470)
Clinical usefulness of magnifying colonoscopy for the diagnosis of ulcerative colitis‐associated neoplasia

Keisuke Kawasaki,Shotaro Nakamura,Motohiro Esaki,Koichi Kurahara,Makoto Eizuka,Yoichiro Nuki,Shuji Kochi,Minako Fujiwara,Yumi Oshiro,Tamotsu Sugai,Takayuki Matsumoto

DOI: https://doi.org/10.1111/den.13382

2019-04-01

Digestive Endoscopy

Abstract:The aim of this investigation was to evaluate the efficacy of Japanese magnifying colonoscopic classifications for ulcerative colitis‐associated neoplasia (UCAN).We reviewed the colonoscopy records from 2011 to 2018 at our institutions and identified cases of endoscopically or surgically resected UCAN observed by magnifying narrow‐band imaging (NBI) endoscopy and magnifying chromoendoscopy. Association between magnifying endoscopic classification and histopathological findings was investigated retrospectively. Japan NBI expert team (JNET) classification and pit pattern classification were applied.There were 17 patients who had a diagnosis of UCAN. Tumors of types 2A, 2B and 3 by JNET classification correlated with the histopathological findings of low‐grade dysplasia (LGD)/high‐grade dysplasia (HGD), HGD, and massively submucosal invasive (mSM) carcinoma, respectively. Tumors of types III/IV, VI low irregularity, and VI high irregularity/VN by pit pattern classification were correlated with the histopathological findings of LGD/HGD, HGD, and mSM carcinoma, respectively. Japan NBI expert team classification and pit pattern classification may be predictive of the histological diagnosis and invasion depth of UCAN. This needs to be investigated prospectively in a large cohort or in a randomized clinical trial.

gastroenterology & hepatology,surgery
Effects of desmethylimipramine and diphenylpropene derivatives on synthesis of rat brain lipids in vivo.

P. Johnson,T. J. Rising,D. Trist

DOI: https://doi.org/10.1016/0024-3205(73)90078-7

1973-10-01

Life Science

Abstract:
Identification of immune-associated genes for the diagnosis of ulcerative colitis-associated carcinogenesis via integrated bioinformatics analysis

Xueyu Cang,Ning Li,Jihan Qi,Hongliang Chen,Hui Xing,Jiawei Qiu,Yingying Tian,Shiling Huang,Pengchao Deng,Feiyang Gao,Ram Prasad Chaulagain,Ubaid Ullah,Chunjing Wang,Lina Liu,Shizhu Jin

DOI: https://doi.org/10.3389/fonc.2024.1475189

IF: 4.7

2024-11-09

Frontiers in Oncology

Abstract:Background: UC patients suffer more from colorectal cancer (CRC) than the general population, which increases with disease duration. Early colonoscopy is difficult because ulcerative colitis-associated colorectal cancer (UCAC) lesions are flat and multifocal. Our study aimed to identify promising UCAC biomarkers that are complementary endoscopy strategies in the early stages. Methods: The datasets may be accessed from the Gene Expression Omnibus and The Cancer Genome Atlas databases. The co-expressed modules of UC and CRC were determined via weighted co-expression network analysis (WGCNA). The biological mechanisms of the shared genes were exported for analysis using the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes. To identify protein interactions and hub genes, a protein-protein interaction network and CytoHubba analysis were conducted. To evaluate gene expression, external datasets and experimental validation of human colon tissues were utilized. The diagnostic value of core genes was examined through receiver operating characteristic (ROC) curves. Immune infiltration analysis was employed to investigate the associations between immune cell populations and hub genes. Results: Three crucial modules were identified from the WGCNA of UC and CRC tissues, and 33 coexpressed genes that were predominantly enriched in the NF-κB pathway were identified. Two biomarkers (CXCL1 and BCL6) were identified via Cytoscape and validated in external datasets and human colon tissues. CRC patients expressed CXCL1 at the highest level, whereas UC and CRC patients showed higher levels than the controls. The UC cohort expressed BCL6 at the highest level, whereas the UC and CRC cohorts expressed it more highly than the controls. The hub genes exhibited significant diagnostic potential (ROC curve > 0.7). The immune infiltration results revealed a correlation among the hub genes and macrophages, neutrophils and B cells. Conclusions: The findings of our research suggest that BCL6 and CXCL1 could serve as effective biomarkers for UCAC surveillance. Additionally, they demonstrated a robust correlation with immune cell populations within the CRC tumour microenvironment (TME). Our findings provide a valuable insight about diagnosis and therapy of UCAC.

oncology
Treatment of gingival recession with coronally advanced flap procedures: a systematic review.

F. Cairo,U. Pagliaro,M. Nieri

DOI: https://doi.org/10.1111/j.1600-051X.2008.01267.x

IF: 7.478

2008-09-01

Journal Of Clinical Periodontology

Abstract:BACKGROUND The treatment of buccal gingival recessions is a common requirement due to aesthetic concern or root sensitivity. The aim of this manuscript was to systematically review the literature on coronally advanced flap (CAF) alone or in combination with tissue grafts, barrier membranes (BM), enamel matrix derivative (EMD) or other material for treating gingival recession. MATERIAL AND METHODS Randomized clinical trials on treatment of Miller Class I and II gingival recessions with at least 6 months of follow-up were identified. Data sources included electronic databases and hand-searched journals. The primary outcome variable was complete root coverage (CRC). The secondary outcome variables were recession reduction, clinical attachment gain, keratinized tissue gain, aesthetic satisfaction, root sensitivity, post-operative patient pain and complications. RESULTS A total of 794 Miller Class I and II gingival recessions in 530 patients from 25 RCTs were evaluated in this systematic review. CAF was associated with mean recession reduction and CRC. The addition of connective tissue graft (CTG) or EMD enhanced the clinical outcomes of CAF in terms of CRC, while BM did not. The results with respect to the adjunctive use of acellular dermal matrix were controversial. CONCLUSIONS CTG or EMD in conjunction with CAF enhances the probability of obtaining CRC in Miller Class I and II single gingival recessions.
A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer

Yuji Toiyama,Yoshinaga Okugawa,Koji Tanaka,Toshimitsu Araki,Keiichi Uchida,Asahi Hishida,Motoi Uchino,Hiroki Ikeuchi,Seiichi Hirota,Masato Kusunoki,C Richard Boland,Ajay Goel

DOI: https://doi.org/10.1053/j.gastro.2017.08.037

IF: 29.4

Gastroenterology

Abstract:Background & aims: Methylation of specific microRNAs (miRNAs) often occurs in an age-dependent manner, as a field defect in some instances, and may be an early event in colitis-associated carcinogenesis. We aimed to determine whether specific mRNA signature patterns (MIR1, MIR9, MIR124, MIR137, MIR34B/C) could be used to identify patients with ulcerative colitis (UC) who are at increased risk for colorectal neoplasia. Methods: We obtained 387 colorectal tissue specimens collected from 238 patients with UC (152 without neoplasia, 17 with dysplasia, and 69 with UC-associated colorectal cancer [UC-CRC]), from 2 independent cohorts in Japan between 2005 and 2015. We quantified methylation of miRNAs by bisulfite pyrosequencing analysis. We analyzed clinical data to determine whether miRNA methylation patterns were associated with age, location, or segment of the colorectum (cecum, transverse colon, and rectum). Differences in tissue miRNA methylation and expression levels were compared among samples and associated with cancer risk using the Wilcoxon, Mann-Whitney, and Kruskal-Wallis tests as appropriate. We performed a validation study of samples from 90 patients without UC and 61 patients with UC-associated dysplasia or cancer to confirm the association between specific methylation patterns of miRNAs in non-tumor rectal mucosa from patients with UC at risk of UC-CRC. Results: Among patients with UC without neoplasia, rectal tissues had significantly higher levels of methylation levels of MIR1, MIR9, MIR124, and MIR137 than in proximal mucosa; levels of methylation were associated with age and duration of UC in rectal mucosa. Methylation of all miRNAs was significantly higher in samples from patients with dysplasia or CRC compared with samples from patients without neoplasia. Receiver operating characteristic analysis revealed that methylation levels of miRNAs in rectal mucosa accurately differentiated patients with CRC from those without. Methylation of MIR137 in rectal mucosa was an independent risk factor for UC-CRC. Methylation patterns of a set of miRNAs (panel) could discriminate discriminate UC patients with or without dysplasia or CRC in the evaluation cohort (area under the curve, 0.81) and the validation cohort (area under the curve, 0.78). Conclusions: In evaluation and validation cohorts, we found specific miRNAs to be methylated in rectal mucosal samples from patients with UC with dysplasia or CRC compared with patients without neoplasms. This pattern also associated with patient age and might be used to identify patients with UC at greatest risk for developing UC-CRC. Our findings provide evidence for a field defect in rectal mucosa from patients with UC-CRC.
Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes

Keijiro Mizukami,Yusuke Iwasaki,Eiryo Kawakami,Makoto Hirata,Yoichiro Kamatani,Koichi Matsuda,Mikiko Endo,Kokichi Sugano,Teruhiko Yoshida,Yoshinori Murakami,Hidewaki Nakagawa,Amanda B Spurdle,Yukihide Momozawa

DOI: https://doi.org/10.1016/j.ebiom.2020.103033

IF: 11.205

EBioMedicine

Abstract:Background: National Comprehensive Cancer Network (NCCN) recently recommended germline genetic testing for all pancreatic cancer patients. However, the genes targeted by genetic testing and the feasibility of selecting patients likely to carry pathogenic variants have not been sufficiently verified. The purpose of this study was to genetically characterize Japanese patients and examine whether the current guideline is applicable in this population. Methods: Using targeted sequencing, we analyzed the coding regions of 27 cancer-predisposing genes in 1,005 pancreatic cancer patients and 23,705 controls in Japan. We compared the pathogenic variant frequency between cases and controls and documented the demographic and clinical characteristics of carrier patients. We then examined if it was possible to use machine learning to predict carrier status based on those characteristics. Findings: We identified 205 pathogenic variants across the 27 genes. Pathogenic variants in BRCA2, ATM, and BRCA1 were significantly associated with pancreatic cancer. Characteristics associated with carrier status were inconsistent with previous investigations. Machine learning classifiers had a low performance in determining the carrier status of pancreatic cancer patients, while the same classifiers, when applied to breast cancer data as a positive control, had a higher performance that was comparable to that of the NCCN guideline. Interpretation: Our findings support the clinical significance of multigene panel testing for pancreatic cancer and indicate that at least 3.4% of Japanese patients may respond to poly (ADP ribose) polymerase inhibitor treatments. The difficulty in predicting carrier status suggests that offering germline genetic testing for all pancreatic cancer patients is reasonable. Funding: AMED under Grant Number JP19kk0305010 and Australian National Health and Medical Research funding (ID177524).
Single-cell and microarray chip analysis revealed the underlying pathogenesis of ulcerative colitis and validated model genes in diagnosis and drug response

Luo, Baiwei,Chen, Keren

DOI: https://doi.org/10.1007/s13577-022-00801-6

2022-11-30

Human Cell

Abstract:The morbidity rate of ulcerative colitis (UC) in the world is increasing year by year, recurrent episodes of diarrhea, mucopurulent and bloody stools, and abdominal pain are the main symptoms, reducing the quality of life of the patient and affecting the productivity of the society. In this study, we sought to develop robust diagnostic biomarkers for UC, to uncover potential targets for anti-TNF-ɑ drugs, and to investigate their associated pathway mechanisms. We collected single-cell expression profile data from 9 UC or healthy samples and performed cell annotation and cell communication analysis. Revealing the possible pathogenesis of ulcerative colitis by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) analysis. Based on the disease-related modules obtained from weighted correlation network analysis (WGCNA) analysis, we used Lasso regression analysis and random forest algorithm to identify the genes with the greatest impact on disease (EPB41L3, HSD17B3, NDRG1, PDIA5, TRPV3) and further validated the diagnostic value of the model genes by various means. To further explore the relationship and mechanism between model genes and drug sensitivity, we collected gene expression profiles of 185 UC patients before receiving anti-tumor necrosis factor drugs, and we performed functional analysis based on the results of differential analysis between NR tissues and R tissues, and used single-sample GSEA (ssGSEA) and CIBERSORT algorithms to explore the important role of immune microenvironment on drug sensitivity. The results suggest that our model is not only helpful in aiding diagnosis, but also has implications for predicting drug efficacy; in addition, model genes may influence drug sensitivity by affecting immune cells. We suggest that this study has developed a diagnostic model with higher specificity and sensitivity, and also provides suggestions for clinical administration and drug efficacy prediction.

cell biology
Ulcerative colitis-associated neoplasms often harbor poor prognostic histologic components with low detection by biopsy

Ryoya Sakakibara,Shinya Sugimoto,Kaoru Takabayashi,Hiroki Kiyohara,Yusuke Wakisaka,Yuta Kaieda,Miho Kawaida,Yusuke Yoshimatsu,Tomohisa Sujino,Naoki Hosoe,Motohiko Kato,Masayuki Shimoda,Yohei Mikami,Yasushi Iwao,Takanori Kanai

DOI: https://doi.org/10.5217/ir.2024.00006

Abstract:Background/aims: Poorly differentiated adenocarcinoma, signet-ring cell carcinoma, and mucinous adenocarcinoma (por/sig/muc), which are considered to be histologic subtypes with a poor prognosis, occur more frequently with colitis-associated cancer than with sporadic tumors. However, their invasiveness and manifestations are unclear. This study aimed to determine the prevalence of the por/sig/muc component in ulcerative colitis-associated neoplasms (UCANs) and its association with invasiveness and to clarify its clinicohistologic and endoscopic features. Methods: This retrospective observational study included patients diagnosed with ulcerative colitis-associated high-grade dysplasia or adenocarcinoma from 1997 to 2022 who were divided according to the presence or absence of a por/sig/muc component. Results: Thirty-five patients had UCAN with a por/sig/muc component and 66 had UCAN without this component. The 5-year survival rate was significantly lower in the por/sig/muc group than in the tub group (67% vs. 96%, P= 0.001), which was attributed to disease above stage III and depth to below the subserosa. Biopsy-based diagnosis before resection detected a por/sig/muc component in only 40% of lesions (14/35). Lesions with a por/sig/muc component were prevalent even in the early stages: stage 0 (4/36, 11%), I (8/20, 40%), II (7/12, 58%), III (10/14, 71%), and IV (6/8, 75%). Conclusions: This is the first investigation that shows UCANs with a por/sig/muc component tended to be deeply invasive and were often not recognized preoperatively. Endoscopists should be aware that UCAN often has a por/sig/muc component that is not always recognized on biopsy, and the optimal treatment strategy needs to be carefully considered.
Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias

Kazuo Konishi,Lanlan Shen,Suna Wang,Stephen J Meltzer,Noam Harpaz,Jean-Pierre J Issa

DOI: https://doi.org/10.1053/j.gastro.2007.01.035

IF: 29.4

Gastroenterology

Abstract:Background & aims: We previously reported that a high degree of age-related methylation was found in both the dysplastic and nondysplastic mucosa of patients with ulcerative colitis (UC). Whether this translates into hypermethylation in UC-associated cancers (UC-Cs) is not known. Methods: We evaluated the methylation status of 11 genes (MINT1, 2, 31, hMLH1, p16, p14, MGMT, HPP1, SFRP1, ERalpha, and LINE-1) in 48 UC-Cs, 21 UC-associated dysplasias, and 69 sporadic colorectal cancers (S-CRCs) using a quantitative bisulfite pyrosequencing analysis. Results: Methylation levels in UC-Cs were lower than S-CRCs for all the genes except MGMT. A methylation index based on the average of Z-scores, for type C (cancer-specific genes: MINT1, MINT2, MINT31, hMLH1, p16, and p14) was -.97 in UC-Cs and .92 in S-CRCs (P = .009). That of type A (age-related genes: HPP1, SFRP1, and ERalpha) was -1.97 in UC-Cs and 1.24 in S-CRCs (P < .001). We observed a significant difference in the incidence of CpG island methylator phenotype between UC-Cs and S-CRCs (8 of 48 [17%] and 26 of 69 [38%]; P = .022). UC-associated dysplasias had significantly higher methylation of type A gene than UC-Cs (Z-score: .07 and -1.97, respectively; P < .001). By contrast, global DNA methylation measured using a LINE-1 assay was significantly higher in UC-Cs than in S-CRCs (58.2% vs 51.0%, P < .001). Conclusions: DNA methylation alterations are uncommon in UC cancers. Given that both genetic and epigenetic changes are common in UC mucosa and dysplasias, we speculate that the genetic changes lead to a more aggressive clinical course than epigenetic changes.
Identification of Polymorphisms in Ultraconserved Elements (uces) Associated with Clinical Outcomes in Patients (pts) with Stage Ii/Iii Colorectal Cancer (Crc).

M. Lin,E. Hawk,M. Huang,J. Lin,J. Gu,M. Ellis,X. Wu,C. Eng

DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.3529

IF: 45.3

2011-01-01

Journal of Clinical Oncology

Abstract:3529 Background: Recent studies have not demonstrated therapeutic advances in pts with stage II-III CRC indicating the need for novel methodology. UCEs are non-coding sequences with 100% sequence identity among orthologous genomic regions of human and murine species. UCEs harbor critical biologic functions including splicing, epigenetics, and transcriptional coactivation. Our analysis aims to determine whether single nucleotide polymorphisms (SNPs) within UCEs correlate with outcomes in CRC pts receiving adjuvant 5-FU based chemotherapy. METHODS AJCC stage II-III pts (diagnosed < 1 yr) had blood and epidemiological data collected. Forty-eight SNPs within UCEs were genotyped. The validation set comprised pts with a history of recurrence (diagnosed > 1 yr). Association between genotypes, recurrence, and survival was conducted using Cochrane Q, K-M, and log-rank testing. RESULTS Of 662 pts, 285 of 435 pts [66%: stage II/III(N=115/170)] and 227 pts [stage II/III (N=88/112] comprised the training and validation sets, respectively. Median follow-up was 45.1 months. In stage II pts, increased recurrent risk (IRR) for rs7849 was noted in the training (HR: 2.39; 95%CI: 1.04-5.52), replication (HR: 3.70; 95%CI: 1.42-9.64) and meta-analysis sets (HR: 2.89; 95%CI: 1.54-5.41). IRR was observed in pts with one variant allele of rs2421099 (HR: 2.44; 95%CI: 1.08-5.51), rs16983007 (HR: 2.81; 95% CI: 1.02-7.70), or homozygous variant of rs10211390 (HR: 2.79; 95%CI: 1.16-6.71). In stage III pts, reduced RR occurred with at least one variant allele of rs6124509 (HR: 0.38; 95%CI: 0.16-0.91) and rs11195893 (HR: 0.26; 95%CI: 0.08-0.91); homozygous variant rs10211390 resulted in IRR (HR: 2.70; 95%CI: 1.12-6.50). Multiple risk genotypes had a dose-dependent effect on RR in stage II/III pts (p < 0.01). CONCLUSIONS This is the first reported analysis of SNPs within UCEs in CRC following adjuvant 5-FU based therapy. A total of 5 SNP's were associated with IRR in stage II/III pts; two SNPs resulted in a reduced RR in stage III pts. Identification of these variations suggests they have a biologic role in recurrence and may contribute prognostically to therapeutic decisions.
Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer

MASAYOSHI KOBAYASHI,NAGAHIDE MATSUBARA,YUTAKA NAKACHI,YASUSHI OKAZAKI,MOTOI UCHINO,HIROKI IKEUCHI,JIHYNG SONG,KEI KIMURA,MICHIKO YASUHARA,AKIHITO BABAYA,TOMOKI YAMANO,MASATAKA IKEDA,HIROKI NISHIKAWA,IKUO MATSUDA,SEIICHI HIROTA,NAOHIRO TOMITA

DOI: https://doi.org/10.21873/invivo.11745

2019-12-27

In Vivo

Abstract:Background/Aim: The difficulty of early diagnosis of colitis associated colorectal cancer (CACRC) due to colonic mucosal changes in long-standing ulcerative colitis (UC) patients is often experienced in daily clinical practice. Noninvasive objective monitoring for cancer development is advantageous for optimizing treatment strategies in UC patients. We aimed to examine the epigenetic alterations occurring in CACRC, focusing on DNA hypermethylation of CpG islands. Materials and Methods: The level of DNA methylation in CpG cites was compared between CACRC and the counterpart non-tumorous mucosa using Infinium HumanMethylation 450K BeadChip. Results: Our subjects included 3 males and 3 females (median age, 49.5 years). The 450K CpG site DNA methylation microarray revealed that the difference in β value (level of hypermethylation) was the highest for corcicotropin releasing hormone receptor 2 (CRHR2) between CACRC and counterpart non-tumorous mucosa. Conclusion: Detection of hypermethylation of CRHR2 may be promising for cancer screening in UC patients.

medicine, research & experimental
Pgpm_a_274258 707..718

Chao-Yi Ge,Li-Yuan Wei,Yu Tian,Hua-Hong Wang

2020-01-01

Abstract:*These authors contributed equally to this work Purpose: Ulcerative colitis (UC) patients have an increased risk of colorectal cancer (CRC), and compared with sporadic CRC, ulcerative colitis-associated colorectal cancer (CAC) is more aggressive with a worse prognosis. This study aimed to identify a gene signature to predict the risk of CAC for patients with UC in remission. Patients and Methods: Series of quiescent UC-related transcriptome data obtained from the Gene Expression Omnibus (GEO) data set were divided into a training set and a validation set. Gene Set Variation Analysis (GSVA), Gene Set Enrichment Analysis (GSEA), and \Weighted Correlation Network Analysis (WGCNA) combined with protein– protein interaction (PPI) analysis were used to identify the pathways and gene signatures related to tumorigenesis among quiescent UC patients. A generalized linear model (GLM) of Poisson regression based on the training set was applied to estimate the diagnostic power of the gene signature in our validation set. Results: The tumor necrosis factor (TNF) signaling via NF-κB pathway was significantly augmented with the highest normalized enrichment score (NES). The genes in the brown module from WGCNA have shown a significant correlation with CAC (Pearson coefficient = 0.83, p = 6e-06). A subset of NF-κB related genes (FOS, CCL4, CXCL1, MYC, CEBPB, ATF3, and JUNB) were identified with a relatively higher expression level in CAC samples. The diagnostic value of this 7-gene biomarker was estimated by the receiver operating characteristic (ROC) curve with an area under the ROC curve (AUC) at 0.82 (p<0.0001, 95% CI: 0.7098–0.9400) in the validation cohort. Conclusion: In summary, the increased expression of this seven-NF-κB-related gene signature may act as a powerful index for tumorigenesis prediction among patients with UC in remission.
Usefulness of genotyping APC gene for individualizing management of patients with familial adenomatous polyposis

Yoshiko Mori,Hideyuki Ishida,Noriyasu Chika,Tetsuya Ito,Kunihiko Amano,Kenichi Chikatani,Yoji Takeuchi,Mitsuhiro Kono,Satoki Shichijo,Akiko Chino,Toshiya Nagasaki,Akinari Takao,Misato Takao,Sakiko Nakamori,Kazuhito Sasaki,Kiwamu Akagi,Tatsuro Yamaguchi,Kohji Tanakaya,Tomita Naohiro,Yoichi Ajioka

DOI: https://doi.org/10.1007/s10147-023-02419-6

2023-10-20

International Journal of Clinical Oncology

Abstract:Colorectal polyp burden is crucial for the management of patients with familial adenomatous polyposis (FAP). However, accurate evaluation of polyp burden is difficult to standardize. This study aimed to examine the possible utility of genotype-oriented management of colorectal neoplasms in patients with FAP.

oncology
Clinical Assessment and Genetic Testing for Hereditary Polyposis Syndromes in an Italian Cohort of Patients with Colorectal Polyps

Candida Fasano,Filomena Cariola,Giovanna Forte,Antonia Lucia Buonadonna,Paola Sanese,Andrea Manghisi,Martina Lepore Signorile,Katia De Marco,Valentina Grossi,Vittoria Disciglio,Cristiano Simone

DOI: https://doi.org/10.3390/cancers16213617

2024-10-27

Cancers

Abstract:Background: Hereditary polyposis syndromes are clinically and genetically heterogeneous conditions associated with increased colorectal cancer risk. They are classified based on polyp histology, inheritance mode, causal gene, and colonic and extracolonic manifestations. Their diagnosis is challenging due to overlapping and heterogeneous clinical presentations. Methods: A multigene next-generation sequencing panel was used to screen 75 index cases with colorectal polyps and a personal/family history of cancer for key hereditary polyposis-associated genes (APC, BMPR1A, MUTYH, PTEN, SMAD4, and STK11) in order to identify germline genetic variants. Results: In the screened index cases, we found 14 pathogenic variants involving APC, MUTYH, SMAD4, and STK11 and 6 variants of uncertain significance involving APC, BMPR1A, and SMAD4. In this cohort, four patients not fulfilling the recommended eligibility criteria of current National Comprehensive Cancer Network (NCCN) guidelines for genetic testing were molecularly diagnosed with a hereditary polyposis syndrome. Conclusions: Our findings indicate that stringent NCCN eligibility criteria for molecular screening may lead to missing some of the patients affected by hereditary polyposis syndromes. This highlights the need for a careful evaluation of patients' clinical manifestations, polyp number, age of polyp onset, and family history to select appropriate candidates for molecular diagnosis of these conditions.

oncology

Favorable Outcome in a Pregnancy With Complete Fetal Heart Block and Severe Bradycardia

Genetic Analysis of Biopsy Tissues from Colorectal Tumors in Patients with Ulcerative Colitis

P412 Time trend in clinicopathological features and prognosis of Ulcerative Colitis associated neoplasia: A nationwide cohort in Japan

Molecular characterization of ulcerative colitis-associated colorectal carcinomas

Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer

Ki‐67 distribution, α‐methylacyl‐CoA racemase (AMACR) expression and mucin phenotypes are associated with non‐polypoid growth in ulcerative colitis‐associated neoplasia

Gene Signature Distinguishes Patients with Chronic Ulcerative Colitis Harboring Remote Neoplastic Lesions

Clinical usefulness of magnifying colonoscopy for the diagnosis of ulcerative colitis‐associated neoplasia

Effects of desmethylimipramine and diphenylpropene derivatives on synthesis of rat brain lipids in vivo.

Identification of immune-associated genes for the diagnosis of ulcerative colitis-associated carcinogenesis via integrated bioinformatics analysis

Treatment of gingival recession with coronally advanced flap procedures: a systematic review.

A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer

Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes

Single-cell and microarray chip analysis revealed the underlying pathogenesis of ulcerative colitis and validated model genes in diagnosis and drug response

Ulcerative colitis-associated neoplasms often harbor poor prognostic histologic components with low detection by biopsy

Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias

Identification of Polymorphisms in Ultraconserved Elements (uces) Associated with Clinical Outcomes in Patients (pts) with Stage Ii/Iii Colorectal Cancer (Crc).

Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer

Pgpm_a_274258 707..718

Usefulness of genotyping APC gene for individualizing management of patients with familial adenomatous polyposis

Clinical Assessment and Genetic Testing for Hereditary Polyposis Syndromes in an Italian Cohort of Patients with Colorectal Polyps